Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2431 to 2445 of 9128 results

  1. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    Technology appraisal guidance Reference number: TA1177 Published:  14 July 2026

    Technology appraisal guidance
    Awaiting development

  2. Osimertinib for adjuvant treatment of EGFR mutation-positive stage 1A2 or 1A3 non-small-cell lung cancer after complete tumour resection

    Awaiting development Reference number: GID-TA12457 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. SKY-0515 for treating Huntington's disease [TSID12429]

    Awaiting development Reference number: GID-TA12476 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 10 August 2026.

    Technology appraisal guidance
    In consultation

  5. Garetosmab for preventing heterotopic ossification and flare ups associated with fibrodysplasia ossificans progressiva [ID3772]

    In development Reference number: GID-TA12522 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    In development Reference number: GID-TA10868 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  7. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment ID6463: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 12 August 2026.

    Technology appraisal guidance
    In consultation

  8. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment ID6463

    In development Reference number: GID-TA11590 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]

    In development Reference number: GID-TA11651 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 15 July 2026.

    Technology appraisal guidance
    In consultation

  11. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 30 July 2026.

    Technology appraisal guidance
    In consultation

  12. Obsessive-compulsive disorder and body dysmorphic disorder

    In development Reference number: GID-QS10200 Expected publication date:  24 March 2027

    Quality standard
    In development

  13. Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset [TSID10190]

    Awaiting development Reference number: GID-TA11283 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129]

    Awaiting development Reference number: GID-TA11698 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Aficamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6668]

    Awaiting development Reference number: GID-TA11877 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development